Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines. 1996

A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD 20892-4255, USA.

Cyclin-dependent kinase-4 inhibitor genes (INK4) regulate the cell cycle and are candidate tumor-suppressor genes. To determine if alterations in the coding regions of the p18 and p19 genes, which are novel members of the INK4 family and if they correlate with the development of human cancer, 100 human cancer cell lines were analyzed. Two other INK4 gene family members, p15INK4b/MTS2 and p16INK4/MTS1 genes were also analyzed. Homozygous deletions of the p15INK4b/MTS2 gene were detected in 29 cancer cell lines. Thirty-five homozygous deletions and 7 intragenic mutations of the pl6INK4/MTS1 gene were also detected in these cell lines. Neither homozygous deletions nor intragenic mutations of the p18 and p19 genes were found except in an ovarian cancer cell line, SKOV3, harboring a single base pair deletion in exon 1 of p19. In p16INK4/MTS1 expression analysis, 5 cell lines with both authentic and alternative spliced p16INK4/MTS1 mRNA had no detectable p16INK4/MTS1 protein. These results suggest the hypotheses that either post-translational modification or enhanced degradation may be responsible for the lack of detection of the p16INK4/MTS1 protein. Using Western blot analysis, subsets of 26 human cancer cell lines were examined for p18 expression and 39 cell lines for p19 expression. All of these cell lines expressed the p18 or p19 protein, with the exception of SKOV3, which did not express p19. Therefore, the INK4 gene family may be divided into 2 groups. One group includes p15INK4b/MTS2 and p16INK4/MTS1, in which genetic and epigenetic alterations might contribute to the development of human cancers. The other group includes p18 and p19, in which somatic mutations are uncommon in many types of human cancer, and their role in human carcinogenesis and cancer progression is uncertain.

UI MeSH Term Description Entries
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D050764 Cyclin-Dependent Kinase Inhibitor p19 An INK4 cyclin-dependent kinase inhibitor containing five ANKYRIN REPEATS. Aberrant expression of this protein has been associated with TESTICULAR CANCER. CDKN2D Protein,Cyclin-Dependent Kinase Inhibitor 2D,INK4D Protein,p19INK4D Protein,Cyclin Dependent Kinase Inhibitor 2D,Cyclin Dependent Kinase Inhibitor p19
D018797 Cell Cycle Proteins Proteins that control the CELL DIVISION CYCLE. This family of proteins includes a wide variety of classes, including CYCLIN-DEPENDENT KINASES, mitogen-activated kinases, CYCLINS, and PHOSPHOPROTEIN PHOSPHATASES as well as their putative substrates such as chromatin-associated proteins, CYTOSKELETAL PROTEINS, and TRANSCRIPTION FACTORS. Cell Division Cycle Proteins,Cell-Cycle Regulatory Proteins,cdc Proteins,Cell Cycle Regulatory Proteins
D018844 Cyclin-Dependent Kinases Protein kinases that control cell cycle progression in all eukaryotes and require physical association with CYCLINS to achieve full enzymatic activity. Cyclin-dependent kinases are regulated by phosphorylation and dephosphorylation events. Cyclin-Dependent Kinase,Cyclin-Dependent Protein Kinase,cdk Proteins,Cyclin-Dependent Protein Kinases,Cyclin Dependent Kinase,Cyclin Dependent Kinases,Cyclin Dependent Protein Kinase,Cyclin Dependent Protein Kinases,Kinase, Cyclin-Dependent,Kinase, Cyclin-Dependent Protein,Protein Kinase, Cyclin-Dependent
D019941 Cyclin-Dependent Kinase Inhibitor p16 A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions. CDKN2 Protein,CDKN2A Protein,Cdk4-Associated Protein p16,Cyclin-Dependent Kinase Inhibitor-2A,INK4A Protein,MTS1 Protein,Multiple Tumor Suppressor-1,p16(INK4A),p16INK4 Protein,p16INK4A Protein,Cdk4 Associated Protein p16,Cyclin Dependent Kinase Inhibitor 2A,Cyclin Dependent Kinase Inhibitor p16,Multiple Tumor Suppressor 1,Protein, INK4A

Related Publications

A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
April 1995, Cancer research,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
June 1997, Experimental cell research,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
March 1997, Leukemia research,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
December 1995, Molecular carcinogenesis,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
February 1996, Cancer,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
December 1995, Journal of molecular evolution,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
July 1995, Blood,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
November 1995, International journal of cancer,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
December 1994, Genes & development,
A Gemma, and S Takenoshita, and K Hagiwara, and A Okamoto, and E A Spillare, and M G McMemamin, and S P Hussain, and K Forrester, and M Zariwala, and Y Xiong, and C C Harris
July 1995, Cancer research,
Copied contents to your clipboard!